Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON D GOLDMAN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1740436609
CMS profile
953859
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$17,574.00

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $8,925.00 3
Gilead Sciences, Inc. $8,649.00 4

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON D GOLDMAN

NPI 1740436609 · CMS profile ID 953859

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740436609?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740436609?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740436609?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740436609?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $17,574.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $3,675.0009/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819141699 CMS
Lilly USA, LLC $2,100.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818575203 CMS
Lilly USA, LLC $3,150.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819155991 CMS
Gilead Sciences, Inc. $1,575.0007/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845882121 CMS
Gilead Sciences, Inc. $2,587.5006/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845882119 CMS
Gilead Sciences, Inc. $3,226.5005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845882117 CMS
Gilead Sciences, Inc. $1,260.0003/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845882115 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $122.85 1
PY2021 $17,574.00 7
PY2022 $15,210.91 14
PY2023 $13,287.42 14
PY2024 $11,764.44 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $158,197.00 5
PY2024 Principal investigator $90,056.83 3
PY2023 Principal investigator $165,634.58 75
PY2022 Principal investigator $250,665.41 168
PY2021 Principal investigator $1,865,002.79 46
PY2020 Principal investigator $3,623,465.43 32
PY2019 Principal investigator $21,772.20 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,574.89 10/11/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977076673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,830.38 10/11/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977076679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,088.92 10/11/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977076685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.61 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.37 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.99 10/02/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076661
Principal investigator 1 Gilead Sciences, Inc. $82,658.00 06/05/2023 Covered Recipient Teaching Hospital
Swedish Issaquah
Will Antiviral Treatment with Remdesivir during Acute COVID-19 Reduce the Incidence of Long COVID? A retrospective cohort analysis of hospitalized patients with COVID-19 in the Providence St. Joseph Health system. No dispute reported 06/30/2026 1025312739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32,025.90 05/25/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977076429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32,395.33 05/25/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977076435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 01/30/2023 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS No dispute reported 06/30/2026 977076399